Table 2. Main clinical treatment results and adverse events in somatostatin and terlipressin groups.

	Somatostatin group (N = 41)	Terlipressin group (N = 109)	P value
Initial hemostasis (within 48 h)	40 (97.6%)	108 (99.1%)	0.473
Rebleeding
Very early rebleeding (49–120 h)	1 (2.5%)	1 (0.9%)	0.469
Early rebleeding (6–42 d)	4 (10.0%)	14 (13.0%)	0.781
–Sources of early rebleeding
Esophageal varices	3 (7.5%)	10 (9.3%)	1.000
EVL-induced ulcer	1 (2.5%)	4 (3.7%)	1.000
Gastric varices/PHG	0 (0.0%)	0 (0.0%)	1.000
Mortality at 6 wk	4 (9.8%)	14 (12.8%)	0.419
–Cause of death
EV bleeding	3 (2.8%)	7 (6.4%)	1.000
Liver failure	0 (0%)	3 (2.8%)	0.562
Bacterial peritonitis	1 (2.4%)	2 (1.8%)	1.000
Hepatorenal syndrome	0 (0%)	1 (0.9%)	1.000
Pneumonia	0 (0%)	1 (0.9%)	1.000
Blood transfusion (unit)	4.6 ± 5.7	4.0 ± 3.6	0.421
Hospital stay (day)	8.1 ± 2.8	8.9 ± 4.0	0.240
Probable adverse events	13 (31.7%)	36 (33.0%)	0.878
–Vasoactive agent-related
Chest tightness/pain	6 (14.6%)	23 (21.1%)	0.488
Hypertension (SBP >140 mmHg)	5 (12.2%)	26 (23.9%)	0.116
Abdominal pain	2 (4.9%)	12 (11.0%)	0.352
Arrhythmia	1 (2.4%)	4 (3.7%)	1.000
Hyponatremia (Na <125 mmol/L)	2 (4.9%)	18 (16.5%)	0.103
Lymphangitis	0 (0%)	6 (5.5%)	0.189
Renal failure (Cr >2 mg/dL)	4 (9.8%)	3 (2.8%)	0.089
Hyperglycemia (Glu >300 mg/dL)	2 (4.9%)	4 (3.7%)	0.665
Flush	1 (2.4%)	3 (2.8%)	1.000
–EVL-associated
Chest tightness/pain	6 (14.6%)	23 (21.1%)	0.488
Retrosternal pain	5 (12.2%)	18 (16.5%)	0.617
Dysphagia/odynophagia	1 (2.4%)	2 (1.8%)	1.000
Post-EVL ulcer	4 (9.8%)	13 (11.9%)	1.000
Esophageal stricture	0 (0%)	0 (0%)	1.000

Notes.

EV

esophageal varix

EVL

endoscopic variceal ligation

PHG

portal hypertensive gastropathy

SBP

systolic blood pressure